Weight-loss drug developer BioAge raises $198 million in U.S. IPO
BioAge Labs has raised $198 million after pricing its upsized U.S. initial public offering at the midpoint of the range at $18 per share, the weight-loss drug developer said on Wednesday. The surging popularity of weight-loss drugs,
California-based biotech BioAge Labs will have its initial public offering of stock. The company is developing Azelaprag, a ...
BioAge Labs is bringing in almost $200 million via its Nasdaq IPO this morning, with the proceeds earmarked for taking its ...
BioAge Labs has completed its upsized initial public offering (IPO), raising $198 million after increasing the number of ...
The offering, which was upsized twice, will support development of a drug the company believes can boost the effects of popular weight loss medicines like Eli Lilly’s Zepbound.
BioAge Labs Inc., which has turned its aging diseases focus toward the hot area of obesity drugs, hopes to raise up to close ...
BioAge Labs is eyeing around $180 million in initial proceeds from an IPO and a private placement, funds the ...
BKV misses IPO price range Denver-based BKV's IPO priced below its ... energy basins with production declines that take much longer than others, he noted. BioAge Labs prices at $18 a share ...
BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United States, the obesity drug developer said on Wednesday, in a sign of strong demand from ...
A California biotech that began as an anti-aging company, then licensed an Amgen heart failure drug for $1 million upfront ...
The U.S. IPO market looks stable this week, with a few new companies aiming to raise capital, as the Federal Reserve reduced ...
Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback